CymaBay Therapeutics Inc. (CBAY)
Total Valuation
CBAY has a market cap or net worth of $234.56 million. The enterprise value is $125.22 million.
| Market Cap | 234.56M |
| Enterprise Value | 125.22M |
Important Dates
The next earnings date is Thursday, August 11, 2022, after market close.
| Estimated Earnings Date | Aug 11, 2022 |
| Ex-Dividend Date | n/a |
Share Statistics
CBAY has 84.68 million shares outstanding. The number of shares has increased by 27.35% in one year.
| Shares Outstanding | 84.68M |
| Shares Change (YoY) | +27.35% |
| Shares Change (QoQ) | +13.64% |
| Owned by Insiders (%) | 0.39% |
| Owned by Institutions (%) | 79.38% |
| Float | 62.12M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 2.18 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.68, with a Debt / Equity ratio of 0.74.
| Current Ratio | 13.68 |
| Quick Ratio | 13.43 |
| Debt / Equity | 0.74 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
Financial Efficiency
Return on equity (ROE) is -92.30%, which is considered low. The company has a ROIC of -85.00%.
| Return on Equity (ROE) | -92.30% |
| Return on Assets (ROA) | -62.40% |
| Return on Capital (ROIC) | -85.00% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.70M |
| Employee Count | 59 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -36.47% in the last 52 weeks. The beta is 1.08, so CBAY's price volatility has been similar to the market average.
| Beta (1Y) | 1.08 |
| 52-Week Price Change | -36.47% |
| 50-Day Moving Average | 2.20 |
| 200-Day Moving Average | 2.82 |
| Average Volume (30 Days) | 790,070 |
Short Selling Information
The latest short interest is 3.35 million, so 3.95% of the outstanding shares have been sold short.
| Short Interest | 3.35M |
| Short % of Shares Out | 3.95% |
| Short % of Float | 5.38% |
| Short Ratio (days to cover) | 5.45 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -94.47M |
| Net Income | -100.22M |
| EBITDA | -93.58M |
| EBIT | -94.27M |
| Earnings Per Share (EPS) | -$1.32 |
Balance Sheet
The company has $188.56 million in cash and $79.22 million in debt, giving a net cash position of $109.34 million or $1.29 per share.
| Cash & Cash Equivalents | 188.56M |
| Total Debt | 79.22M |
| Net Cash | 109.34M |
| Net Cash Per Share | $1.29 |
| Book Value | 107.38M |
| Book Value Per Share | 1.27 |
| Working Capital | 178.01M |
Cash Flow
In the last 12 months, operating cash flow was -$74.23 million and capital expenditures $7,000, giving a free cash flow of -$74.23 million.
| Operating Cash Flow | -74.23M |
| Capital Expenditures | 7,000 |
| Free Cash Flow | -74.23M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CBAY does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Earnings Yield | -42.73% |
| FCF Yield | -31.64% |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -27.35% |
| Shareholder Yield | -27.35% |
Analyst Forecast
The average price target for CBAY is $10.09, which is 264.26% higher than the current price. The consensus rating is "Buy".
| Price Target | $10.09 |
| Price Target Difference | 264.26% |
| Analyst Consensus | Buy |
| Analyst Count | 14 |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |